EUCTR2017-002300-27-GB进行中（未招募）1 期
Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III Squamous Cell Carcinoma of Anus - CORINTH
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •In order to be eligible for participation in this trial, the subject must:
- •1. Be willing and able to provide written informed consent/assent for the trial.
- •2. Age 18 years or over on day of signing informed consent.
- •3. Histologically proven Squamous Cell Cancer of Anus (SCCA) Stage IIIA/B (T3/4, +/- any N, M0) anal cancer or highly suspicious and confirmed by the MDT
- •4. Be willing to provide tissue sample either archival or repeat biopsy to be tested for HPV and p16.
- •5. Have a performance status of 0 or 1 on the ECOG Performance Scale.
- •6. Demonstrate adequate organ function performed within 10 days of treatment initiation.
- •a. Haematological: Absolute neutrophil count (ANC) =1.5 x 109/L, Platelets =100 x 109/L, Haemoglobin =9 g/dL or =5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment)
- •b. Coagulation: International Normalized Ratio (INR) or Prothrombin Time (PT)
- •=1.5 X ULN (unless subject is receiving anticoagulant therapy as long as PT
- •or PTT is within therapeutic range of intended use of anticoagulants),
- •Activated Partial Thromboplastin Time (aPTT) =1.5 X ULN (unless subject is
- •receiving anticoagulant therapy as long as PT or PTT is within therapeutic
- •range of intended use of anticoagulants).
- •c. Renal: Serum creatinine =1.5 X upper limit of normal (ULN) OR Measured or
- •calculated creatinine clearance (GFR can also be used in place of creatinine
- •or CrCl) =60 mL/min for subject with creatinine levels > 1.5 X institutional
- •d. Hepatic Serum total bilirubin = 1.5 X ULN OR Direct bilirubin = ULN for
- •subjects with total bilirubin levels > 1.5 ULN
- •7. Female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •8. Female subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in Section 15.9 – Contraception and pregnancy, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
- •9.Male subjects of childbearing potential must agree to use an adequate method of contraception as outlined in Section 15.9- Contraception and pregnancy, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •The subject must be excluded from participating in the trial if the subject:
- •1. Has malignant tumour of non-epithelial origin (sarcoma)
- •2. Has any metastatic disease
- •3. Is unsuitable for radical CRT for whatever reason
- •4. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- •5. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Patients on long-term physiological doses of steroid (¬<10mg prednisolone or equivalent) are eligible.
- •6. Has a known history of active TB (Bacillus Tuberculosis)
- •7. Hypersensitivity to pembrolizumab or any of its excipients.
- •8. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- •9. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent.
- •a. Note: Subjects with = Grade 2 neuropathy are an exception to this
- •criterion and may qualify for the study.
- •b. Note: If subject received major surgery, they must have recovered
- •adequately from the toxicity and/or complications from the intervention prior
- •to starting therapy.
- •10. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer or previous VIN (vulval intra-epithelial neoplasia) or vulval cancer adequately treated, or previous adequately treated breast cancer / DCIS > 5 years ago.
- •11. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •12. Has known history of, or any evidence of active, non-infectious pneumonitis.
- •13. Has an active infection requiring systemic therapy.
- •14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
- •15. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •16. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- •17. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
- •18. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
- •19. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g. HCV RNA is detected). Testing on
研究者
相似试验
招募中
4 期
The CORINTH Trial: Study of Checkpoint Inhibitor Pembrolizumab plus standard chemoradiation in anal cancerAnal cancer2024-515369-33-00Cardiff University3
招募中
2 期
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 InactivationMetastatic Castration Resistant Prostate CancerNCT04104893VA Office of Research and Development40
终止
1 期
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant RecurrenceMultiple MyelomaLymphomaNCT02681302Hackensack Meridian Health46
已完成
2 期
Phase II trial on Programmed death-One inhibitor plus RadioThERapy in patients with Metastatic Mucosal MelanomaMetastatic Mucosal MelanomaJPRN-UMIN000030533Kyoto University20
招募中
2 期
Phase II trial on Programmed death-One inhibitor plus RadioThERapy in patients with Metastatic Mucosal MelanomaMelanomaJPRN-jRCT1051200028omura Motoo20